Clinical Evidence: How These Weight Loss Medicines Compare
Average Weight Loss on Wegovy vs Mounjaro: The Clinical Picture
Understanding the average weight loss on Wegovy compared to Mounjaro requires examining their distinct mechanisms and clinical outcomes. Wegovy utilises semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones, whilst Mounjaro contains tirzepatide, which targets both GLP-1 and GIP receptors for dual-hormone appetite control. In the pivotal STEP 1 trial, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo treatment.
Mounjaro's SURMOUNT trials demonstrated its own impressive results, though direct comparison of trial percentages isn't meaningful due to different study designs and patient populations. What matters most is that both prescription-only medicines offer clinically significant weight management potential when used as part of a comprehensive treatment plan. The average weight loss on Wegovy has been sustained over two years in STEP 5 extension studies, showing 15.2% maintained weight reduction with continued treatment.
Wegovy vs Mounjaro Pricing: Complete Cost Comparison
EverydayMeds offers transparent pricing for both treatments, helping you understand the investment in your weight management journey. Wegovy pricing follows the dose escalation schedule: 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose at £209.99. Our Getting Started bundles provide convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, covering your first 8 weeks of treatment.
Mounjaro follows a similar graduated approach with six available strengths from 2.5mg to 15mg, allowing for personalised dose optimisation based on your response and tolerability. New customers apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 to access our competitive pricing structure. Both treatments qualify for next-day cold-chain delivery once your clinical assessment is approved by our GPhC-registered prescribers (#9012878), ensuring you receive genuine medicine in perfect condition.
STEP Trial Evidence: What Average Weight Loss on Wegovy Means
The landmark STEP clinical programme provides robust evidence for average weight loss on Wegovy across diverse patient populations. STEP 1 enrolled adults with obesity or overweight with weight-related complications, demonstrating that 68-week treatment with Wegovy alongside lifestyle interventions resulted in approximately 15% average weight loss (Wilding et al., NEJM, 2021). STEP 3 combined Wegovy with intensive behavioural therapy, achieving around 16% average weight loss in participants who completed the study protocol.
STEP 5's two-year extension data reveals crucial insights about sustained weight management, with participants maintaining 15.2% average weight loss on Wegovy when continuing treatment. The recent SELECT cardiovascular outcomes trial showed an additional benefit: 20% reduction in major cardiovascular events (HR 0.80) in adults with established cardiovascular disease, highlighting Wegovy's potential beyond weight management alone.
How Wegovy Works: The GLP-1 Mechanism Behind Average Weight Loss
Wegovy's impressive average weight loss results stem from its action as a GLP-1 receptor agonist, closely mimicking the natural incretin hormone GLP-1 that your intestine produces after eating. This prescription-only medicine binds to GLP-1 receptors in your brain's appetite control centres, specifically the hypothalamus, reducing hunger signals and enhancing feelings of satiety after smaller meals. The weekly injection provides sustained hormone levels, helping maintain consistent appetite suppression throughout your treatment week. Unlike rapid-acting appetite suppressants, Wegovy's mechanism promotes gradual, sustainable weight loss by allowing you to feel satisfied with appropriate portion sizes. Clinical studies suggest this approach may also reduce food cravings and emotional eating patterns, contributing to the substantial average weight loss on Wegovy observed in controlled trials.
Your Wegovy Journey: From Assessment to Delivery
Starting your weight management journey with Wegovy begins with our streamlined 3-minute online clinical assessment, designed to evaluate your suitability for this prescription-only medicine safely and efficiently. Our qualified prescribers, operating under GPhC registration #9012878, review your medical history, current medications, and weight management goals within 24-48 hours for express service or 3 working days for standard processing. Once approved, your Wegovy pen ships via temperature-controlled next-day delivery, maintaining the cold-chain integrity essential for this biological medicine. Our clinical team provides comprehensive guidance on injection technique, dose escalation timing, and how to maximise your potential for achieving the average weight loss on Wegovy seen in clinical trials. You'll receive detailed information about the mandatory 4-week intervals between dose increases, ensuring safe progression from the 0.25mg starter dose to your optimal maintenance level.
Storage and Practical Considerations: Wegovy vs Mounjaro Differences
Understanding storage requirements helps you choose between these weight loss medicines based on your lifestyle needs, particularly regarding the average weight loss on Wegovy achievable with proper medication handling. Wegovy pens require refrigeration at 2-8°C before first use but offer superior travel flexibility, remaining stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration. This compares favourably to Mounjaro's 21-day room temperature limit, making Wegovy more suitable for extended travel or business trips. Both medicines use pre-filled FlexTouch pen devices for weekly self-injection, with Wegovy's 5-dose escalation schedule (0.25mg to 2.4mg) compared to Mounjaro's 6 available strengths up to 15mg. The injection experience is similar between treatments, with most patients finding the process straightforward after initial training from our clinical support team.
Maximising Average Weight Loss on Wegovy: The Complete Treatment Approach
Achieving optimal average weight loss on Wegovy requires understanding that this prescription-only medicine works best as part of a comprehensive lifestyle modification programme. Clinical trials demonstrating 15% average weight loss consistently combined Wegovy with reduced-calorie diets and increased physical activity, emphasising that medication alone isn't sufficient for maximum results. Your prescriber will discuss realistic expectations based on individual factors like starting BMI, metabolic health, and commitment to dietary changes alongside your Wegovy treatment.
The STEP trial protocols included structured dietary counselling and exercise guidance, contributing to the impressive average weight loss on Wegovy observed in controlled studies. NICE guidance TA875 recommends Wegovy alongside specialist weight management support, recognising that sustainable results require behavioural changes reinforced by the medicine's appetite-suppressing effects. Regular monitoring helps optimise your dose timing and identify any adjustments needed to maintain steady progress throughout your weight management journey.
Choose Your Treatment: Both Available from EverydayMeds
As the UK's leading online weight management pharmacy, EverydayMeds uniquely stocks both Wegovy and Mounjaro, allowing our prescribers to recommend the most suitable treatment based on your individual circumstances rather than limited availability. Whether you're drawn to Wegovy's proven track record of 15% average weight loss or interested in Mounjaro's dual-hormone approach, our clinical team provides impartial guidance based on your medical history, lifestyle factors, and treatment preferences. Complete your confidential assessment today using discount code FIRST40 for new customers or DOSE25 for returning patients, with both treatments available for next-day delivery once approved. Visit https://everydaymeds.co.uk/collections/weight-loss to start your personalised weight management journey with the confidence that comes from expert clinical oversight and genuine prescription medicines. Our GPhC-registered pharmacy (#9012878) ensures you receive the highest standard of pharmaceutical care throughout your treatment experience.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
